Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.
暂无分享,去创建一个
Devjit Tripathy | G. Bray | S. Mudaliar | T. Buchanan | R. DeFronzo | A. Kitabchi | R. Henry | P. Reaven | N. Musi | F. Stentz | R. Ratner | S. Clement | M. Banerji | D. Tripathy | Robert R Henry | Robert E Ratner | Nicolas Musi | Thomas A Buchanan | Ralph A DeFronzo | Peter D Reaven | George A Bray | Abbas E Kitabchi | MaryAnn Banerji | Sunder Mudaliar | D. Schwenke | Frankie B Stentz | Dawn C Schwenke | Stephen C Clement
[1] S. Yusuf,et al. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes , 2010, Diabetologia.
[2] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[3] Ralph A. DeFronzo,et al. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.
[4] L. J. Hardies,et al. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. , 2007, Diabetologia.
[5] K. Watson,et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study , 2012, The Lancet.
[6] Dream On Investigators. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes , 2011 .
[7] S. Saydah,et al. Trends in Death Rates Among U.S. Adults With and Without Diabetes Between 1997 and 2006 , 2012, Diabetes Care.
[8] Devjit Tripathy,et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. , 2011, The New England journal of medicine.
[9] G. Bray,et al. Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW , 2014, Diabetes Care.
[10] S. Fowler,et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. , 2005, Diabetes.
[11] R. Muniyappa,et al. The diabetes prevention program , 2003, Current diabetes reports.
[12] M. Laakso,et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.
[13] T. Valle,et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.
[14] Haiying Chen,et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. , 2012, JAMA.
[15] G. Bray,et al. Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study , 2012, Diabetes Care.
[16] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[17] Y. Miyazaki,et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. , 2004, The Journal of clinical endocrinology and metabolism.
[18] B. Zinman,et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.
[19] T. Buchanan,et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. , 2006, Diabetes.
[20] T. Buchanan. (How) Can We Prevent Type 2 Diabetes? , 2007, Diabetes.
[21] P. Watkins,et al. Hepatic dysfunction associated with troglitazone. , 1998, The New England journal of medicine.
[22] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[23] L. J. Hardies,et al. Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus , 2007, Diabetologia.
[24] Robert R. Henry,et al. Prevention of Diabetes With Pioglitazone in ACT NOW , 2013, Diabetes.
[25] David M Nathan,et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.
[26] T. Buchanan,et al. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. , 1998, Controlled clinical trials.
[27] G. Bray,et al. Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk , 2013, Diabetes Care.
[28] P. Bennett,et al. The natural history of impaired glucose tolerance in the Pima Indians. , 1988, The New England journal of medicine.
[29] C. Caspersen,et al. Secular Changes in U.S. Prediabetes Prevalence Defined by Hemoglobin A1c and Fasting Plasma Glucose , 2013, Diabetes Care.
[30] J. Shaw,et al. Lifetime risk and projected population prevalence of diabetes , 2008, Diabetologia.